These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 27565933

  • 1. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
    Hamasaki M, Matsumoto S, Abe S, Hamatake D, Kamei T, Hiroshima K, Kawahara K, Sato A, Tsujimura T, Nakatani Y, Yoshida Y, Iwasaki A, Nabeshima K.
    Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
    [Abstract] [Full Text] [Related]

  • 2. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T, Matsumoto S, Hamasaki M, Kawahara K, Tsujimura T, Hiroshima K, Kamei T, Taguchi K, Iwasaki A, Oda Y, Honda H, Nabeshima K.
    Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
    [Abstract] [Full Text] [Related]

  • 3. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
    Ito T, Hamasaki M, Matsumoto S, Hiroshima K, Tsujimura T, Kawai T, Shimao Y, Marutsuka K, Moriguchi S, Maruyama R, Miyamoto S, Nabeshima K.
    Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
    [Abstract] [Full Text] [Related]

  • 4. Short 57 kb CDKN2A FISH probe effectively detects short homozygous deletion of the 9p21 locus in malignant pleural mesothelioma.
    Oyama Y, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Nabeshima K.
    Oncol Lett; 2021 Dec; 22(6):813. PubMed ID: 34671427
    [Abstract] [Full Text] [Related]

  • 5. The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
    Kulduk G, Ekinci Ö, Toker G, Demirci U, Özaydın E, Akyürek N, Memiş L.
    Pathol Res Pract; 2019 Jun; 215(6):152377. PubMed ID: 30885529
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.
    Nabeshima K, Matsumoto S, Hamasaki M, Hida T, Kamei T, Hiroshima K, Tsujimura T, Kawahara K.
    Diagn Cytopathol; 2016 Sep; 44(9):774-80. PubMed ID: 27219841
    [Abstract] [Full Text] [Related]

  • 13. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
    Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
    [Abstract] [Full Text] [Related]

  • 14. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
    Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Iwasaki A, Nabeshima K.
    Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
    Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H.
    Virchows Arch; 2008 Dec; 453(6):627-35. PubMed ID: 18958493
    [Abstract] [Full Text] [Related]

  • 16. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G, Özekinci S.
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
    Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S.
    Mod Pathol; 2008 Jun; 21(6):742-7. PubMed ID: 18327208
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L, Le Stang N, Gallob F, Pissaloux D, Sequeiros R, Paindavoine S, Pairon JC, Karanian M, Dacic S, Girard N, Churg A, Tirode F, Galateau-Salle F.
    Arch Pathol Lab Med; 2023 Mar 01; 147(3):313-322. PubMed ID: 35738002
    [Abstract] [Full Text] [Related]

  • 20. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
    Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A.
    Pathol Int; 2010 May 01; 60(5):395-9. PubMed ID: 20518890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.